How do you pay?
How many tablets?

How to pay the least

Lowest without a membership

$12.51 for 30 tablets delivered ($7.26 plus $5.25 shipping)

Generic gemfibrozil 600 mg from Cost Plus Drugs, by mail

What to do

  1. Make a free account on costplusdrugs.com. Ask your prescriber to send the prescription there, or Cost Plus Drugs can transfer it.Open Cost Plus Drugs 
  2. Order generic gemfibrozil 600 mg. It comes by mail.

Other ways

Need it today? $15.52 for 30 tablets with the free Team Cuban Card, at pharmacies that take it. Get the free card and show it there.

See the price and get the card 

For 3 months at a time $17 for a 90-day supply from Rx Outreach, by mail. Ask your prescriber to write it for 90 days.

Open Rx Outreach 

With a membership $8.49 for 30 tablets from Amazon Pharmacy, by mail ($139 a year).

Open Amazon Pharmacy 

Every company’s gemfibrozil is rated by the FDA to work the same, so any pharmacy can fill your prescription with the one it stocks.

See every pharmacy’s price

Where to buy it

Pharmacies’ own cash prices for generic gemfibrozil, lowest first.

Pick up in storeDelivered

From each pharmacy’s own site, read November 17, 2026. Confirm the price before you fill.

About these prices

Prices change, can differ by store and state, and may depend on the strength and how many you take. With insurance, ask what your plan charges; it can be less.

Who makes it

7 companies sell gemfibrozil in this form, each one rated by the FDA as a substitute for the others. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.

  • Aurobindo Pharma600 mg

    Product page on aurobindousa.com

    How it looks, what’s in it, NDCs

    600 mg White to Off-white, oval, 19 mm, marked “E / 82”

    PackageNDC
    Bottle of 6065862-624-60
    Bottle of 50065862-624-05

    Inactive ingredients: calcium stearate, silicon dioxide, hypromellose 2910 (6 mpa.s), low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose (1600000 wamw), microcrystalline cellulose, polyethylene glycol 400, polysorbate 80, starch, corn, titanium dioxide

    FDA label

  • Camber Pharmaceuticals600 mg

    Made by Ascent Pharmaceuticals

    Product page on camberpharma.com

    How it looks, what’s in it, NDCs

    600 mg White, oval, 18 mm, marked “1”

    PackageNDC
    Bottle of 6031722-128-60
    Bottle of 50031722-128-05

    Inactive ingredients: starch, corn, microcrystalline cellulose, povidone, silicon dioxide, polysorbate 80, croscarmellose sodium, calcium stearate, hydroxypropyl cellulose, talc

    FDA label

  • Chartwell RX600 mg
    How it looks, what’s in it, NDCs

    600 mg White to off-white, oval, 19 mm, marked “C / E / 51”

    PackageNDC
    Bottle of 6062135-160-60
    Bottle of 30062135-160-31

    Inactive ingredients: calcium stearate, silicon dioxide, hydroxypropyl cellulose, hypromellose, microcrystalline cellulose 101, polyethylene glycol 400, polysorbate 80, starch, corn, sodium starch glycolate type a potato, titanium dioxide, water

    FDA label

  • Cipla600 mg

    Made by Invagen Pharmaceuticals

    How it looks, what’s in it, NDCs

    600 mg White, oval, 19 mm, marked “225 / IG”

    PackageNDC
    Bottle of 6069097-821-03
    Bottle of 10069097-821-07
    Bottle of 50069097-821-12

    Inactive ingredients: silicon dioxide, croscarmellose sodium, calcium stearate, microcrystalline cellulose, methylcellulose (15 mpa.s), hypromellose 2910 (3 mpa.s), hypromellose 2910 (6 mpa.s), polyethylene glycol 400, polysorbate 80

    FDA label

  • Exelan Pharmaceuticals600 mg

    Made by Invagen Pharmaceuticals

    How it looks, what’s in it, NDCs

    600 mg White, capsule, 19 mm, marked “I / G / 225”

    PackageNDC
    Bottle of 6076282-225-60
    Bottle of 18076282-225-18
    Bottle of 50076282-225-05

    Inactive ingredients: silicon dioxide, croscarmellose sodium, calcium stearate, microcrystalline cellulose, methylcellulose (15 cps), hypromellose 2910 (3 mpa.s), hypromellose 2910 (6 mpa.s), polyethylene glycol 400, polysorbate 80

    FDA label

  • NorthStar Rx600 mg

    Made by Aurobindo Pharma

    Product page on northstarrxllc.com

    How it looks, what’s in it, NDCs

    600 mg Off-white, oval, 19 mm, marked “N111”

    PackageNDC
    Bottle of 6016714-101-02
    Bottle of 50016714-101-05

    600 mg White to Off-white, oval, 19 mm, marked “E / 82”

    PackageNDC
    Bottle of 6072603-206-01
    Bottle of 50072603-206-02

    Inactive ingredients: cellulose, microcrystalline, hydroxypropyl cellulose, low substituted, sodium starch glycolate type a potato, titanium dioxide, hypromelloses, polysorbate 80, silicon dioxide, magnesium stearate, hydroxypropyl cellulose, starch, corn, calcium stearate, hypromellose 2910 (6 mpa.s), low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose (1600000 wamw), microcrystalline cellulose, polyethylene glycol 400

    FDA label

  • Rising Pharma Holdings600 mg

    Made by Aurobindo Pharma

    How it looks, what’s in it, NDCs

    600 mg White to Off-white, oval, 19 mm, marked “E / 82”

    PackageNDC
    Bottle of 6016571-784-06
    Bottle of 50016571-784-50

    Inactive ingredients: calcium stearate, silicon dioxide, hypromellose 2910 (6 mpa.s), low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose (1600000 wamw), microcrystalline cellulose, polyethylene glycol 400, polysorbate 80, starch, corn, titanium dioxide

    FDA label

Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.

What to say at the pharmacy

“Before you fill it, what would I pay for generic gemfibrozil?”

Paying cash? Ask for the cash price. With insurance, ask what your plan charges.

What it’s used for

In the words of its FDA label:

Gemfibrozil Tablets are indicated as adjunctive therapy to diet for:

1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2,000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia.

2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS, PRECAUTIONS, and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease. Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NON-CORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL-CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY.

In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I).

The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet.

Source: the FDA label for Gemfibrozil (Cipla USA Inc.), June 18, 2021. Full label on DailyMed 

Good to know

  • Different companies’ gemfibrozil can look different. The FDA requires each to work the same way.
  • Don’t stop or change a medicine without talking to your pharmacist or prescriber.